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CASE REPORT
Response to isolated limb perfusion 
and chemotherapy with epirubicin 
plus ifosfamide in a metastatic malignant 
ossifying fibromyxoid tumor
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Abstract 
Background: Ossifying fibromyxoid tumor (OFMT) is a rare soft tissue neoplasm of uncertain lineage and intermedi-
ate biological potential. It is more common in middle-aged men, usually arising from the deep tissues of the extremi-
ties. It is now established that it is a translocation related tumor, most often marked by translocation of PHF1 gene. 
Surgery is the mainstay of treatment and proves usually curative, although, in rarer cases the disease shows malignant 
features and tendency to recur both locally and at distant sites. In such cases, no standard treatment exists.
Case presentation: We report on a case of malignant advanced OFMT of the hand with lung metastases responding 
to isolated limb perfusion with human recombinant tumor necrosis factor and melphalan and chemotherapy with 
epirubicin and ifosfamide.
Conclusions: To our knowledge, this is the first report of activity of soft tissue sarcoma-oriented chemotherapy in 
advanced OFMT.
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Background
Ossifying fibromyxoid tumor (OFMT) is a rare soft tis-
sue tumor, originally described by Enzinger and Weiss 
in 1989 [1], and currently classified among neoplasms of 
uncertain origin and intermediate-grade behavior in the 
last WHO soft tissue tumors classification [2].
It usually onsets in middle-age, although cases have 
been reported in patients 14–79  years old, more com-
monly in males than females. Most cases arise as small, 
painless, subcutaneous masses often attached to the 
underlying tendons, fascia or skeletal muscle generally 
located at the extremities. Primary tumors of the trunk or 
the retroperitoneum are rarer [2].
OFMT consists of lobules of uniform, round to fusi-
form-shaped cells arranged in nests and cords in a set of 
variable fibromyxoid stroma usually surrounded by an 
incomplete shell of metaplastic, hypocellular, lamellar 
bone. However, this shell may lack in the so-defined non-
ossifying OFMT. Mitotic activity is usually poor, count-
ing for less than 1 per 10 high-power fields (HPF). Rarely, 
OFMT shows hypercellularity and increased number 
of mitotic figures with deposition of tumor osteoid that 
may simulate an osteosarcoma [2]. These variants have 
been described as “atypical” or “malignant”, and have 
been associated to a higher tendency to recur locally or 
metastasize, and to a higher risk of disease-related death 
[3–6], comparable to other soft tissue sarcomas. Overall, 
the local recurrence rate after complete surgical excision 
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ranges between 17 and 27% [3, 6]. Metastases have been 
described only in malignant forms, and, as in other soft 
tissue sarcomas, are more frequent in the lungs and the 
soft tissues. Given the usual intermediate-grade behavior, 
a long survival is possible even in metastatic patients [2, 
6].
It is now established that OFMT is a translocation 
related tumor. Up to 85% of cases carry PHF1 gene trans-
location, without significant differences among typical, 
atypical and malignant forms [7, 8], suggesting a precise 
role of this translocation in oncogenesis, still unknown. A 
possible mechanism of action may be through an epige-
netic effect. Actually, PHF1 has a role in the regulation of 
chromatin structure, interacting with EZH1, EZH2 and 
SUZ12 [8]. Obviously, seeking the translocation is useful 
in differential diagnosis with other soft tissue neoplasms. 
Novel fusions involving BCOR, BCORL1 and WWTR1 
have been reported [9, 10].
Complete surgical resection is usually curative and is 
the mainstay of treatment in the localized setting. In con-
trast, no standard exists in metastatic patients.
We report on a case of recurrent, advanced OFMT 
of the hand with multiple, bilateral, synchronous, lung 
metastases responding to treatments commonly used for 
other soft tissue sarcomas.
Case presentation
In June 2016, a 47-year-old man, in good performance 
status, presented at our Institution (Fondazione IRCCS 
Istituto Nazionale dei Tumori, Milan, Italy), with a mul-
tinodular relapse of a low-grade fibromyxoid sarcoma of 
the right hand (Figs.  1a, 2a), diagnosed in the past year 
Fig. 1 Axial contrast enhanced T1-weighted MRI. Pathologic tissue in the hypothenar eminence of the right hand, involving the flexor tendons and 
the spaces between 3rd, 4th and 5th metacarpal bones with intense and homogeneous contrast enhancement (a). Progressive size and contrast 
enhancement reduction after ILP (b), and chemotherapy (c)
Fig. 2 Picture of the patient’s hand. At presentation a the tumor involved widely the hypothenar eminence and medial aspect of the wrist. Seven 
months after ILP b the nodule in the wrist was hardly palpable while the nodule in the hand was smaller and softer
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upon surgery, performed elsewhere, of a 10-cm mass of 
the right palmar hand, originally infiltrating the tendons, 
vessels and nerves of the last two finger rays.
The histopathological review showed a mesenchymal 
tumor arranged in a plexiform growth pattern, com-
posed of small round cells, focal extracellular matrix in 
rose-shaped accumulation, and focal chondroid areas. 
The mitotic count was 14/10 HPF, necrosis was present 
(Fig. 3a). No ossifying shell was present. The diagnosis of 
malignant OFMT was confirmed by FISH test positive 
for PHF gene rearrangement (Fig. 3b).
A whole-body computerized tomography (CT) scan 
showed bilateral, multiple lung metastases (Fig. 4a).
At presentation, due to the extension of the disease 
to the third and fourth interdigital spaces and the distal 
forearm, an upfront surgery would have entailed a fore-
arm amputation. To improve the chance of achieving a 
complete resection with a conservative procedure, in July 
2016 the patient underwent isolated limb perfusion (ILP) 
of the upper right limb using recombinant human tumor 
necrosis factor (TNF) and Melphalan. The treatment was 
well tolerated and achieved an excellent clinical and radi-
ological response, i.e. partial response (PR) according to 
RECIST (Fig. 1b).
In September 2016, when a new CT scan showed fur-
ther progression of the lung metastases (Fig.  4b), and 
missing any evidence regarding the effectiveness of sys-
temic treatment in this histotype, the patient under-
went sarcoma-oriented chemotherapy with Epirubicin 
105 mg/sqm and Ifosfamide 9000 mg/sqm + MESNA in 
3  days every 3  weeks. Treatment related adverse events 
were febrile neutropenia, G3 anemia, G3-4 thrombocy-
topenia, and doses were reduced by 20% after the second 
cycle. We observed a PR both on the relapsed primary 
tumor and on the lung metastases after three and six 
cycles (Figs. 1c, 2b, 4c, d).
In February 2017, the Patient underwent complete 
surgery of the local residual disease, with amputation of 
the last two finger rays of his right hand. Therapy related 
changes accounted for 90% of neoplasm mostly com-
posed of fibrosis with haemosiderin (85%) and focally 
by necrosis and ghost cells with loss of nuclear and 
Fig. 3 a Malignant OFMT pre-ILP biopsy, (HE, 40×). Densely packed cords of monomorphic cell with small round nuclei, high mitotic index. b 
Fluorescent in situ hybridization showing tetraploid cells showing unbalanced PHF1 gene translocation (green 5′). c Malignant OFMT post-ILP and 
chemotherapy, vital component (HE, 20×). The neoplasm is less densely cellulated and exhibits a variable morphology ranging from more rounded 
to spindle cell morphology. Mitotic activity is considerably reduced. d Malignant OFMT post-ILP and chemotherapy, non-vital component (HE, 20×). 
At the bottom of the image, a dense collagen sclerosis with haemosiderin deposition, ghost cells at the upper part, in between cell debris and 
isolated neoplastic cells with nuclei similarly to the viable component
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cytoplasmic detail. Viable tumor was mostly located 
proximally, characterized by a heterogeneous morphol-
ogy (Fig.  3c, d). Viable component was R1 on proximal 
resection margin, and palmar margin on soft tissue was 
R1 with therapy related changes.
In March and April 2017, the Patient underwent a 
2-stage complete lung metastasectomy. Vital tumor 
component at the histopathological examination ranged 
between 85 and 100%. First post-treatment follow-up 
radiological evaluation performed in July 2017 resulted 
negative for persistent or relapsed disease.
Discussion and conclusions
OFMT is a rare soft tissue neoplasm usually character-
ized by an intermediate-grade behavior [2]. Surgery is 
usually curative in typical variant, albeit local and distant 
relapses are reported in atypical and malignant subtypes 
[3–6]. There is no standard of treatment in case of meta-
static disease.
We report on a case of advanced, malignant OFMT 
with a local relapse and bilateral lung metastases, treated 
with sarcoma-oriented treatment, and responding to 
ILP and chemotherapy with epirubicin and ifosfamide 
both on local and distant disease. Local tumor shrink-
age enabled to perform a partially conservative surgery. 
The response of the lung metastases was strictly depend-
ent on chemotherapy; indeed, the patient was progress-
ing rapidly before treatment started, and achieved a 
good cytoreduction that led to considering bilateral 
metastasectomy.
ILP with TNF and Melphalan is a procedure that, in 
the setting of limb-threatening extremity STS, aims at 
improving the chance of performing a conservative resec-
tion. In short, it consists of infusion of high-dose TNF 
and melphalan directly in the affected limb under local 
hyperthermia by extracorporeal circulation. Complete 
pathological response after TNF-ILP has been described 
in up to half of cases. Moreover, TNF-ILP leads to dis-
tinct response patterns with devitalization of tumor mar-
gins; close or positive margins at critical structures thus 
may become acceptable. This may lead to conservative 
resections where amputation was planned. In different 
cohort studies, tumor resection and limb salvage in pre-
planned amputations were achieved from 76 to 96% [11].
Anthracycline-based (doxorubicin or epirubicin) 
chemotherapy combinations have been widely used as 
first line treatment of metastatic soft tissue sarcomas 
[12]. The benefit of multi-agent compared to single agent 
anthracycline-based chemotherapy for advanced soft tis-
sue sarcomas remains controversial. In most randomized 
prospective trials, combination regimens were associ-
ated with higher response rates (27–46%), despite a non-
significant overall survival benefit [13, 14]. Indeed, it is 
essential to consider the goal of therapy in definition of 
the treatment plan. Sequential administration of active 
single agents may maximize the duration of disease con-
trol and reduce treatment-associated toxicities. However, 
upfront combination chemotherapy may be of benefit for 
selected patients, e.g. those with a high tumor burden 
requiring a prompt tumor shrinkage or those with a fast-
growing disease: in these cases, the need of obtaining an 
objective response may justify the increased toxicity of 
drug combination.
Of course, it is difficult to conduct prospective trials 
in such a rare histotype, and even collecting clinical evi-
dences from retrospective series becomes problematic, 
especially in the setting of orphan diseases. In fact, all 
published series of patients with OFMT focus on histo-
pathological features and natural history.
Enzinger et al. [1] originally described the first 59 cases, 
with 11 patients experiencing a local relapse and 1 dis-
tant progression. Folpe et  al. [6] analyzed a series of 70 
patients and proposed the classification in “typical”, 
“atypical” and “malignant” types upon cellularity, nuclear 
Fig. 4 Coronal contrast enhanced CT scan. A right lung lower lobe metastases (arrow) at baseline (a), increasing after ILP (b), and progressively 
reducing after 3 (b) and 6 (d) cycles of chemotherapy with epirubicin and ifosfamide
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atypia and mitotic index. In particular, tumors with a 
high nuclear grade and mitosis > 2/50 HPF were associ-
ated to a significant risk of developing distant metasta-
ses, and were labelled as “malignant” forms (6/10 patients 
with these features developed distant metastases, but 
only 1/16 with atypical OFMT, and 1/25 with a typical 
type). Miettinen et al. [3] associated mitosis > 2/50 HPF 
to a higher risk of developing a local relapse, but they 
concluded for a poor metastatic potential. However, their 
consideration may be limited from the high number of 
patients lost to follow-up. Graham et al. [15] observed 3 
distant progressions among 15 patients with malignant 
OFMT, and none among 5 atypical and 26 typical type 
cases. Retrospective series on the natural history coming 
from the biggest series are summarized in Table 1. In all 
series, no data on the activity of chemotherapy have been 
reported [1, 3–6, 15].
Although in a single case, but in a rare disease and in 
absence of any other evidence, we provide data of activity 
of soft tissue sarcoma-oriented treatment in advanced, 
malignant OFMT. As far as we know, this is the first 
report of activity of chemotherapy in this histotype. Even 
though these cases are extremely rare, we believe that 
reporting anecdotal evidence is worth as helping the cli-
nician to manage these patients, providing clinical data 
supporting the medical decision and our comprehension 
of these diseases. In this sense, all attempts of data collec-
tion should be supported and encouraged.
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Table 1 Histopathological and clinical features in published series of patients with OFMT
FU follow-up, T typical, A atypical, M malignant, N/A not available, LR Local relapse, DM distant metastasis, DoC dead of other cause, NED not evident disease, ED 
evident disease, DoD dead of disease, UNK unknown
Study Number of patients 
(total/FU)
Histological subtype (T, 
A, M)
Median follow-up 
(months)
Follow-up information Outcome
Enzinger et al. [1] 59/41 N/A N/A 11 LR
1 DM
3 DoC
Folpe et al. [6] 70/51 N/A 36 9 LR
8 DM
41 NED
6 ED
4 DoD
1 DoC
Miettinen et al. [3] 104/41 N/A 156 9 LR 32 UNK
16 DoC
5 NED
Graham et al. [15] 46/27 T = 26
A = 5 
M = 15
55 2 LR (M)
3 DM (M)
3 DoD
Atanaskova Mesinkova et al. 
[4]
26/16 T = 8
A = 13 
M = 5
45 3 LR (M)
1 DM (M)
N/A
Kossivi Dantey et al. [5] 6/6 A = 1 
M = 5
27 No events 1 DoC
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